A Phase III Randomized, Open-label Study Comparing GSK1120212 to Chemotherapy in Subjects With Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma.

Trial Profile

A Phase III Randomized, Open-label Study Comparing GSK1120212 to Chemotherapy in Subjects With Advanced or Metastatic BRAF V600E/K Mutation-positive Melanoma.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 29 Mar 2017

At a glance

  • Drugs Trametinib (Primary) ; Dacarbazine; Paclitaxel; Vemurafenib
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms METRIC
  • Sponsors GlaxoSmithKline; Novartis Pharma A.G.
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 25 Mar 2017 This trial has been completed in Greece (end date: 16 Dec 2016).
    • 12 Mar 2017 This trial was completed in Belgium, according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top